SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Russell RG, Rogers MJ 1999 Bisphosphonates: From the laboratory to the clinic and back again. Bone 25:97106.
  • 2
    Hughes DE, MacDonald BR, Russell RG, Gowen M 1989 Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83:19301935.
  • 3
    Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA 1996 Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate. Proc Natl Acad Sci USA 93:30683073.
  • 4
    Sato M, Grasser W 1990 Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 5:3140.
  • 5
    Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:14781487.
  • 6
    Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T 1995 A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17:137144.
  • 7
    van Beek ER, Lowik CW, Papapoulos SE 1997 Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. Bone 20:335340.
  • 8
    Hofbauer LC, Heufelder AE 2000 Clinical review 114: Hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:23552363.
  • 9
    Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175179.
  • 10
    Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:35403545.
  • 11
    Hofbauer LC, Heufelder AE 2001 Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243253.
  • 12
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, Takahashi N, Suda T, Higashio K 1999 A novel molecular mechanism modulating osteoclast differentiation and function. Bone 25:109113.
  • 13
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:35973602.
  • 14
    Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:13291337.
  • 15
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165176.
  • 16
    Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ 1993 Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:20042011.
  • 17
    Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N 1996 Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:914.
  • 18
    Vitte C, Fleisch H, Guenther HL 1996 Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:23242333.
  • 19
    Giuliani N, Pedrazzoni M, Passeri G, Girasole G 1998 Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 27:3841.
  • 20
    Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R 1999 Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14:20482056.
  • 21
    Mackie PS, Fisher JL, Zhou H, Choong PF 2001 Bisphosphonates regulate cell growth and gene expression in the UMR 106–01 clonal rat osteosarcoma cell line. Br J Cancer 84:951958.
  • 22
    Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC 2002 Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680686.
  • 23
    Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP 1999 Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274:1361313618.
  • 24
    Schlondorff J, Lum L, Blobel CP 2001 Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J Biol Chem 276:1466514674.
  • 25
    Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A 2002 Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:12281236.
  • 26
    Miyamoto N, Higuchi Y, Mori K, Ito M, Tsurudome M, Nishio M, Yamada H, Sudo A, Kato K, Uchida A, Ito Y 2002 Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol 2:2538.
  • 27
    Slack BE, Ma LK, Seah CC 2001 Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme. Biochem J 357:787794.
  • 28
    Hall A 1998 Rho GTPases and the actin cytoskeleton. Science 279:509514.
  • 29
    Fisher JE, Rodan GA, Reszka AA 2000 In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141:47934796.
  • 30
    Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ 2001 The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:22012210.
  • 31
    Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M, Patella V, Zambonin Zallone A, Grano M 1998 Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 63:230235.
  • 32
    Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:20952105.
  • 33
    Usui T, Tanaka S, Sonoda T, Ozawa Y, Teramura K, Nakamura E, Watanabe T, Higuchi S 1997 Drug disposition of incadronate, a new bisphosphonate, in rats with bone metastases. Xenobiotica 27:479487.
  • 34
    Masarachia P, Weinreb M, Balena R, Rodan GA 1996 Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19:281290.
  • 35
    Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA 1998 An essential role for ectodomain shedding in mammalian development. Science 282:12811284.
  • 36
    Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA 1998 Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273:2776527767.
  • 37
    Schlondorff J, Becherer JD, Blobel CP 2000 Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). Biochem J 347:131138.